Total Payments
$39,805
2024 Payments
$15,465
Companies
9
Transactions
24
Medicare Patients
162
Medicare Billing
$11,954
Payment Breakdown by Category
Research$23,700 (59.5%)
Consulting$15,300 (38.4%)
Food & Beverage$805.13 (2.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $23,700 | 5 | 59.5% |
| Consulting Fee | $15,300 | 3 | 38.4% |
| Food and Beverage | $805.13 | 16 | 2.0% |
Payments by Type
Research
$23,700
5 transactions
General
$16,105
19 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma Global Development | $39,000 | 8 | $0 (2024) |
| Bausch & Lomb Americas Inc. | $216.93 | 2 | $0 (2024) |
| Sight Sciences, Inc. | $180.29 | 3 | $0 (2022) |
| Astellas Pharma US Inc | $146.46 | 2 | $0 (2024) |
| Sun Pharmaceutical Industries Inc. | $128.88 | 2 | $0 (2023) |
| Alcon Vision LLC | $79.32 | 4 | $0 (2024) |
| Beaver-Visitec International, Inc. | $18.72 | 1 | $0 (2023) |
| Aerie Pharmaceuticals, Inc. | $17.27 | 1 | $0 (2021) |
| CooperVision Inc. | $17.26 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $15,465 | 7 | Astellas Pharma Global Development ($15,300) |
| 2023 | $24,100 | 11 | Astellas Pharma Global Development ($23,700) |
| 2022 | $222.51 | 5 | Sight Sciences, Inc. ($180.29) |
| 2021 | $17.27 | 1 | Aerie Pharmaceuticals, Inc. ($17.27) |
All Payment Transactions
24 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $31.46 | General |
| Category: Ophthalmology | ||||||
| 11/20/2024 | Alcon Vision LLC | Rocklatan (Drug) | Food and Beverage | In-kind items and services | $22.03 | General |
| Category: Ophthalmology | ||||||
| 05/13/2024 | Alcon Vision LLC | Rocklatan (Drug) | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: Ophthalmology | ||||||
| 03/12/2024 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $5,100.00 | General |
| Category: Ophthalmology | ||||||
| 03/12/2024 | Bausch & Lomb Americas Inc. | INFUSE (Device) | Food and Beverage | In-kind items and services | $95.71 | General |
| Category: Ophthalmology | ||||||
| 02/13/2024 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $5,100.00 | General |
| Category: Ophthalmology | ||||||
| 01/06/2024 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $5,100.00 | General |
| Category: Ophthalmology | ||||||
| 12/03/2023 | Astellas Pharma Global Development | Izervay (Drug) | — | Cash or cash equivalent | $5,100.00 | Research |
| Study: A Phase 3 Multicenter, Randomized, Double Masked, Sham-Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients with Geographic Atropy Secondary to Age-Related Macular Degeneration • Category: Ophthalmology | ||||||
| 11/02/2023 | Astellas Pharma Global Development | Izervay (Drug) | — | Cash or cash equivalent | $5,100.00 | Research |
| Study: A Phase 3 Multicenter, Randomized, Double Masked, Sham-Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients with Geographic Atropy Secondary to Age-Related Macular Degeneration • Category: Ophthalmology | ||||||
| 10/11/2023 | Sun Pharmaceutical Industries Inc. | Cequa (Drug) | Food and Beverage | In-kind items and services | $100.11 | General |
| Category: Ophthalmology | ||||||
| 10/01/2023 | Astellas Pharma Global Development | Izervay (Drug) | — | Cash or cash equivalent | $4,500.00 | Research |
| Study: A Phase 3 Multicenter, Randomized, Double Masked, Sham-Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients with Geographic Atropy Secondary to Age-Related Macular Degeneration • Category: Ophthalmology | ||||||
| 09/19/2023 | Alcon Vision LLC | Rocklatan (Drug) | Food and Beverage | In-kind items and services | $16.45 | General |
| Category: Ophthalmology | ||||||
| 09/01/2023 | Astellas Pharma Global Development | Izervay (Drug) | — | Cash or cash equivalent | $4,500.00 | Research |
| Study: A Phase 3 Multicenter, Randomized, Double Masked, Sham-Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients with Geographic Atropy Secondary to Age-Related Macular Degeneration • Category: Ophthalmology | ||||||
| 08/10/2023 | Astellas Pharma Global Development | Izervay (Drug) | — | Cash or cash equivalent | $4,500.00 | Research |
| Study: A Phase 3 Multicenter, Randomized, Double Masked, Sham-Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients with Geographic Atropy Secondary to Age-Related Macular Degeneration • Category: Ophthalmology | ||||||
| 08/03/2023 | Beaver-Visitec International, Inc. | — | Food and Beverage | In-kind items and services | $18.72 | General |
| 07/19/2023 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $115.00 | General |
| 07/09/2023 | Sun Pharmaceutical Industries Inc. | Cequa (Drug) | Food and Beverage | In-kind items and services | $28.77 | General |
| Category: Ophthalmology | ||||||
| 06/07/2023 | Bausch & Lomb Americas Inc. | INFUSE (Device) | Food and Beverage | In-kind items and services | $121.22 | General |
| Category: Ophthalmology | ||||||
| 11/15/2022 | Sight Sciences, Inc. | OMNI(R) SURGICAL SYSTEM (US) (Device) | Food and Beverage | In-kind items and services | $46.59 | General |
| Category: Ophthalmology | ||||||
| 11/02/2022 | Sight Sciences, Inc. | OMNI(R) SURGICAL SYSTEM (US) (Device) | Food and Beverage | In-kind items and services | $118.19 | General |
| Category: Ophthalmology | ||||||
| 08/15/2022 | Sight Sciences, Inc. | OMNI(R) SURGICAL SYSTEM (US) (Device) | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: Ophthalmology | ||||||
| 03/26/2022 | CooperVision Inc. | Multiple Brands Contact Lens (Device) | Food and Beverage | In-kind items and services | $17.26 | General |
| Category: Devices | ||||||
| 03/24/2022 | Alcon Vision LLC | AcrySof IQ PanOptix UV IOL (Device) | Food and Beverage | In-kind items and services | $24.96 | General |
| Category: Ophthalmology | ||||||
| 09/23/2021 | Aerie Pharmaceuticals, Inc. | rocklatan (Drug), rhopressa | Food and Beverage | In-kind items and services | $17.27 | General |
| Category: Glaucoma | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3 Multicenter, Randomized, Double Masked, Sham-Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients with Geographic Atropy Secondary to Age-Related Macular Degeneration | Astellas Pharma Global Development | $23,700 | 5 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 104 | 114 | $11,496 | $7,419 |
| 2022 | 2 | 44 | 44 | $5,596 | $3,173 |
| 2021 | 1 | 14 | 14 | $1,703 | $1,363 |
Total Patients
162
Total Services
172
Medicare Billing
$11,954
Procedure Codes
8
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 92014 | Established patient complete exam of visual system | Office | 2023 | 44 | 47 | $5,626 | $3,388 | 60.2% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 19 | 19 | $2,868 | $1,925 | 67.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 19 | 25 | $2,143 | $1,669 | 77.9% |
| 92134 | Imaging of retina | Office | 2023 | 11 | 12 | $460.08 | $300.60 | 65.3% |
| 92133 | Imaging of optic nerve | Office | 2023 | 11 | 11 | $398.83 | $136.40 | 34.2% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 32 | 32 | $3,867 | $2,262 | 58.5% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 12 | 12 | $1,729 | $910.26 | 52.6% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2021 | 14 | 14 | $1,703 | $1,363 | 80.0% |
About Dr. Mara Tresansky, OD
Dr. Mara Tresansky, OD is a Optometrist healthcare provider based in Victor, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/24/2021. The National Provider Identifier (NPI) number assigned to this provider is 1841963071.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mara Tresansky, OD has received a total of $39,805 in payments from pharmaceutical and medical device companies, with $15,465 received in 2024. These payments were reported across 24 transactions from 9 companies. The most common payment nature is "" ($23,700).
As a Medicare-enrolled provider, Tresansky has provided services to 162 Medicare beneficiaries, totaling 172 services with total Medicare billing of $11,954. Data is available for 3 years (2021–2023), covering 8 distinct procedure/service records.
Ad
Practice Information
- Specialty Optometrist
- Location Victor, NY
- Active Since 07/24/2021
- Last Updated 05/19/2025
- Taxonomy Code 152W00000X
- Entity Type Individual
- NPI Number 1841963071
Products in Payments
- Izervay (Drug) $39,031
- INFUSE (Device) $216.93
- OMNI(R) SURGICAL SYSTEM (US) (Device) $180.29
- Cequa (Drug) $128.88
- Rocklatan (Drug) $54.36
- AcrySof IQ PanOptix UV IOL (Device) $24.96
- rocklatan (Drug) $17.27
- Multiple Brands Contact Lens (Device) $17.26
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Optometrist Doctors in Victor
Brian Pratt, O.d, O.D
Optometrist — Payments: $4,463
Optometrist $4,463
Roy Kim, O.d, O.D
Optometrist — Payments: $4,213
Optometrist $4,213
Rashida Clarke, O.d, O.D
Optometrist — Payments: $4,132
Optometrist $4,132
Richard Chute, Od, OD
Optometrist — Payments: $3,607
Optometrist $3,607
Dr. Natasha Decker, O.d, O.D
Optometrist — Payments: $1,225
Optometrist $1,225
Dr. Judith Archer, O.d, O.D
Optometrist — Payments: $1,122
Optometrist $1,122